Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11172546 | 0.86 | RAB9A (0.56) | RAB9ANPC1MMP13ALDH1A1HTT | |
| SCHEMBL19210473 | 0.82 | MMP13 (0.53) | RAB9ANPC1MMP13KMT2AUSP2 | |
| SCHEMBL14524621 | 0.82 | CYP1A2 (0.42) | RAB9ANPC1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL9546454 | 0.81 | ALDH1A1 (0.54) | RAB9ANPC1MMP13ALDH1A1HTT | |
| SCHEMBL3163935 | 0.81 | NPC1 (0.75) | RAB9ANPC1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL27325881 | 0.81 | MMP13 (0.51) | RAB9ANPC1MMP13ALDH1A1HTT | |
| SCHEMBL18997622 | 0.81 | RAB9A (0.46) | RAB9ANPC1MMP13ALDH1A1HTT | |
| SCHEMBL12672893 | 0.80 | USP2 (0.57) | ALDH1A1KMT2AUSP2TSPOHSD17B10 | |
| SCHEMBL6619359 | 0.80 | RIPK1 (0.65) | RAB9ANPC1ALDH1A1KMT2APYGL | |
| SCHEMBL11177738 | 0.79 | MMP13 (0.50) | RAB9ANPC1MMP13ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-5338738-A | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | RAB9A 1952/4885NPC1 3369/4885MMP13 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.